Results 11 to 20 of about 40,526 (207)

Simultaneous Intracranial and Spinal Hemorrhage Following Tenecteplase Thrombolysis for ST-Elevation Myocardial Infarction: A Case Report. [PDF]

open access: yesClin Case Rep
ABSTRACT Central nervous system (CNS) hemorrhage is a serious complication of intravenous thrombolysis. Tenecteplase, a fibrin‐specific thrombolytic agent, has a lower risk of hemorrhage than other agents. We report the first documented case of simultaneous intracranial and spinal hemorrhage following intravenous administration of tenecteplase.
Palliyaguru T   +4 more
europepmc   +2 more sources

A hidden cause of infertility in hypothyroid patients [PDF]

open access: yes, 2020
Methylene tetrahydrofolate reductase (MTHFR) gene mutations could be the cause of infertility in hypothyroid patients. Hence, it is worthy to screen for MTHFR gene mutations in infertile hypothyroid females and their partners if infertility persists ...
Ahmed, Soha Magdy   +4 more
core   +1 more source

Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study

open access: yesEClinicalMedicine, 2020
Background: Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection is associated with hypercoagulability caused by direct invasion of endothelial cells and/or proinflammatory cytokine release.
Filippo Albani   +11 more
doaj   +1 more source

Characterizing the delays in adequate thromboprophylaxis after TBI

open access: yesTrauma Surgery & Acute Care Open, 2021
Background We sought to compare enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in trauma patients with and without traumatic brain injury (TBI) to better understand the time and dose required to reach target anti-Xa levels. Our hypothesis
Eric J Ley   +6 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

open access: yes, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm   +72 more
core   +1 more source

Critically ill patients with edema and ascites may experience subtherapeutic anti-factor Xa levels following abdominal subcutaneous enoxaparin treatment

open access: yesSAGE Open Medical Case Reports, 2022
Enoxaparin is a low molecular weight heparin that is principally prescribed for the treatment and prevention of thromboembolic disorders. In clinical practice, the abdominal site for subcutaneous enoxaparin administration is most preferable because of ...
Vichapat Tharanon   +1 more
doaj   +1 more source

How we treat bleeding associated with direct oral anticoagulants [PDF]

open access: yes, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo   +4 more
core   +1 more source

Cancer and thrombosis: Managing the risks and approaches to thromboprophylaxis [PDF]

open access: yes, 2006
Patients with cancer are at increased risk of venous thromboembolism (VTE) compared with patients without cancer. This results from both the prothrombotic effects of the cancer itself and iatrogenic factors, such as chemotherapy, radiotherapy, indwelling
Altinbas M   +36 more
core   +1 more source

Dosis Efektif Enoxaparin dalam Mencegah Terjadinya Trombosis pada Anastomosis Arteri Femoralis Tikus

open access: yesJBN (Jurnal Bedah Nasional), 2017
Tujuan: untuk mengetahui dosis efektif enoxaparin dalam mencegah terjadinya trombosis pada anastomosis mikrovaskular. Metode: penelitian ini bersifat eksperimental dengan rancangan the randomized post test only control group design.
I Made Suka Adnyana   +1 more
doaj   +1 more source

Where and when to inject low molecular weight heparin in hemodiafiltration? : a cross over randomised trial [PDF]

open access: yes, 2015
Background and Objective : Low molecular weight heparins (LMWHs) are small enough to pass large pore dialysis membranes. Removal of LMWH if injected before the start of the session is possible during high-flux dialysis and hemodiafiltration.
Devreese, Katrien   +5 more
core   +3 more sources

Home - About - Disclaimer - Privacy